The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy

Irinotecan, a standard of care therapy for CRC, elicits cytotoxic effects by generating double strand breaks resulting in DNA damage. The activation of the ATM pathway plays a fundamental role in regulating the cellular response and repair to DNA damage. The objective of this preclinical study was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Greene, Justin, Nguyen, Anna, Bagby, Stacey M., Jones, Gemma N., Tai, WM., Quackenbush, Kevin S., Schreiber, Anna, Messersmith, Wells A., Devaraj, Kalpana M., Blatchford, Patrick, Eckhardt, S. Gail, Cadogan, Elaine B., Hughes, Gareth D., Smith, Aaron, Pitts, Todd M., Arcaroli, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762293/
https://www.ncbi.nlm.nih.gov/pubmed/29340025
http://dx.doi.org/10.18632/oncotarget.22920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762293/
https://www.ncbi.nlm.nih.gov/pubmed/29340025
http://dx.doi.org/10.18632/oncotarget.22920

Ejemplares similares